Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Jamaica
(0/week)
Netherlands Antilles
(0/week)
View all
(0/week)
News
United States
(1211/week)
Manufacturing
(587/week)
Technology
(1160/week)
Energy
(413/week)
aviation
(174/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Mirati Therapeutics, Inc.
Jan 09, 2020
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Jan 08, 2020
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
Jan 06, 2020
Mirati Therapeutics Announces Executive Management Changes
Nov 04, 2019
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
Oct 23, 2019
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
Oct 17, 2019
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Aug 15, 2019
Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources
Aug 05, 2019
Mirati Therapeutics Reports Second Quarter 2019 Financial Results
Jul 09, 2019
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
Jun 27, 2019
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Jun 25, 2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Jun 24, 2019
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
Apr 29, 2019
Mirati Therapeutics Reports First Quarter 2019 Financial Results
Apr 01, 2019
Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
Feb 07, 2019
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
Jan 22, 2019
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Jan 16, 2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Jan 16, 2019
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
Jan 15, 2019
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
Jan 07, 2019
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
‹‹
Page 2
››
Latest News
Jun 17, 2025
AGI Announces Q2 2025 Dividend
Jun 17, 2025
Compass Minerals Closes on Sale of $650 Million Senior Notes due 2030 and Partial Redemption of Senior Notes...
Jun 17, 2025
AIRO Announces Closing of Its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase...
Jun 17, 2025
Duff & Phelps Utility and Infrastructure Fund Inc. Announces Renewal of Share Repurchase Program and...
Jun 17, 2025
Geospace Technologies Corporation Receives Permanent Reservoir Monitoring Contract From Petrobras
Jun 17, 2025
Murphy USA Issues Operations Update
Jun 17, 2025
Xcel Energy Names Ryan Long Executive Vice President and Chief Legal and Compliance Officer
Jun 17, 2025
Rocket Lab Adds Two New Missions to 2025 Electron Launch Manifest, Schedules First Launch in Four Days’ Time
View all News
Agenda
30
September
Portugal
Troia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United Kingdom
London, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events